4//SEC Filing
Bizily Scott 4
Accession 0000950170-24-107903
CIK 0001650648other
Filed
Sep 17, 8:00 PM ET
Accepted
Sep 18, 5:46 PM ET
Size
8.8 KB
Accession
0000950170-24-107903
Insider Transaction Report
Form 4
Bizily Scott
Chief Legal Officer
Transactions
- Exercise/Conversion
Common Stock
2024-09-16$6.49/sh+500$3,245→ 7,281 total - Sale
Common Stock
2024-09-16$16.33/sh−500$8,165→ 6,781 total - Exercise/Conversion
Stock Option (Right To Buy)
2024-09-16−500→ 10,379 totalExercise: $6.49Exp: 2032-06-17→ Common Stock (500 underlying)
Footnotes (2)
- [F1]Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on October 10, 2023.
- [F2]The shares underlying the stock option award shall vest and become exercisable as to 1/48th of the underlying shares on each monthly anniversary of June 16, 2022 (the "Vesting Commencement Date") such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, while the grantee remains a service provider to the Company.
Documents
Issuer
4D Molecular Therapeutics, Inc.
CIK 0001650648
Entity typeother
Related Parties
1- filerCIK 0001920738
Filing Metadata
- Form type
- 4
- Filed
- Sep 17, 8:00 PM ET
- Accepted
- Sep 18, 5:46 PM ET
- Size
- 8.8 KB